Latest / The Vox Markets Podcast
2353: Poolbeg Pharma Secures First Oncology Patent for POLB 001
Poolbeg Pharma announces its first granted patent for POLB 001 in cancer immunotherapy-induced CRS, strengthening its global IP position. The milestone supports future partnering opportunities as the company advances toward key clinical data in 2026.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.